Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects

Pieter Jan De Kam, Annelieke C. Kruithof, Marie José Van Lierop, Matthijs Moerland, Justin Dennie, Matthew D. Troyer, Ronald B. Langdon, David E. Gutstein, Jacobus Burggraaf, Rachid El Galta

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Objective: To investigate the potential effect of sugammadex on anti-Xa anticoagulant activity of enoxaparin and the activated partial thromboplastin time (APTT) of unfractionated heparin (UFH). Methods: This two-part, randomized, double-blind, placebo-controlled, four-period cross-over study was performed in healthy males (18-45 years). In each period, subjects received 40 mg enoxaparin (in part 1), 5,000 units UFH (in part 2), or placebo followed by 4 or 16 mg/kg sugammadex, or placebo. Treatments were separated by ≥ 4 days. Primary endpoints were anti-Xa activity and APTT both time-averaged from 3 to 30 minutes post-dose. Geometric mean ratios (GMRs) and their two-sided 90% confidence limits were calculated for anticoagulant plus sugammadex (4 or 16 mg/kg) vs. anticoagulant plus placebo. The pre-specified threshold for a potential effect of clinical relevance was a 90% upper confidence limit (UCL) > 1.50. Results: In part 1 (n = 13), the 90% UCLs were 1.07 and 1.08 for GMRs of anti-Xa activity after dosing with 4 and 16 mg/kg sugammadex, respectively. In part 2 (n = 43), the 90% UCLs for GMRs of APTT were 1.06 and 1.15. Neither sugammadex dose produced a treatment effect that met the pre-specified criterion for potential clinical relevance. Treatments were generally well tolerated. Conclusions: In healthy subjects, treatment with 4 mg/kg and 16 mg/kg sugammadex did not change either anti-Xa activity or APTT to a clinically meaningful extent following pretreatments with enoxaparin or UFH.

Original languageEnglish
Pages (from-to)631-641
Number of pages11
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume52
Issue number8
DOIs
StatePublished - Aug 2014
Externally publishedYes

Keywords

  • Neuromuscular blockade
  • Rocuronium
  • Surgical thromboprophylaxis
  • Vecuronium
  • γ-cyclodextrin

Fingerprint

Dive into the research topics of 'Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects'. Together they form a unique fingerprint.

Cite this